A unique blend of cutting-edge technologies


We have a unique portfolio of state-of-the-art technologies and in-house expertise. These include, but are not limited to, (un)targeted metabolomics, single-cell isolation and profiling at multiple omics levels, expertise in tumor inflammation and immune infiltration, the (epi)genetic characterization of tumor DNA using high-throughput sequencing and the functional characterization of non-coding RNAs and other epigenetic modulators, phenotyping of numerous spontaneous tumor and preclinical mouse models (breast, melanoma, colon, liver, lung, leukemia, etc.), CRISPR/CAS-based screening technologies, etc.


To support the use and development of this expertise, VIB has set up institutional core facilities that are available to all VIB researchers, including CCB groups, at marginal costs. Moreover, our  researchers have also access to a series of KULEUVEN-funded facilities/initiatives, some of which VIB and/or CCB have invested in, such as the FACS and single cell facilities, and others that are not directly supported by VIB, such as the PDX platform. Apart from these core facilities, CCB has invested significantly into center-specific core facilities in order to better meet the needs and facilitate the implementation of our mission. Notable are the metabolomics facility (led by Bart Ghesquière), the gene transfer unit (managed by Peter Carmeliet), the single cell profiling expertise center of the histopathology unit.